@ADesaiMD

MD, MBA, MPH, FASCO Thoracic/Phase 1 Oncologist @ONealCancerUAB, Assoc. Prof @UABMedicine | Alum @MayoHemeOnc @UConnIM @MDAndersonNews| 🎙️@LungCancerRX

 Birmingham, AL
bit.ly/45RWj88
Joined June 2019
  • Tweets9.8K
  • Following1.6K
  • Followers6.8K
1.6KMedia
As #oncologytrainees prepare for their first #patientencounter, the #SPIKES protocol is often a good starting point. What advise do you have for #trainees when #deliveringbadnews? @marklewismd @NarjustDumaMD @GlopesMd @mtmdphd @VPrasadMDMPH @DevikaDasMD @MayoHemeOnc #HOFellowLife
33
52
5
208
SigVie-002 #ESMO26 (negative): sigvotatug vedotin (IB6 ADC) vs docetaxel, pretreated nsq NSCLC ➡️ mOS 11.9 vs 11.5 mo, HR 0.929 ➡️ mPFS 4.7 vs 4.2 mo, HR 0.844 ➡️ Post hoc 2L: OS HR 0.831, PFS HR 0.795 Why is docetaxel so hard to beat? @LungCancerRx @OncoAlert @oncodaily
2
3
184
OptiTROP-Lung04 final OS #ESMO26: sac-TMT vs platinum-pem post EGFR-TKI, EGFRm NSCLC ➡️ mOS 25.9 vs 17.4 mo, HR 0.69 ➡️ 2-yr OS 54.1 vs 37.2% ➡️ 22.6% of chemo arm later got an ADC; RPSFT HR 0.57 ADC or chemo first after EGFR-TKI? @LungCancerRx @OncoAlert @oncodaily
1
1
157
Krascendo 1 #ESMO26: divarasib vs sotorasib/adagrasib, pretreated KRAS G12C NSCLC ➡️ mPFS 9.8 vs 5.7 mo, HR 0.58 ➡️ mOS 17.7 vs 12.0 mo, HR 0.56 ➡️ ORR 58 vs 32% ➡️ G3-4 TRAEs 24.6 vs 34.5%; diarrhea 66 vs 38% Where does first-gen G12C fit? @LungCancerRx @OncoAlert @oncodaily
2
5
231
SAFFRON #ESMO26: osi+savo vs platinum-pem post-osimertinib, EGFRm MET OE/amp NSCLC ➡️ mPFS 7.6 vs 5.4 mo, HR 0.55 ➡️ mOS 17.8 vs 12.9 mo, HR 0.68 ➡️ ORR 51 vs 27% ➡️ G≥3 TRAEs 40 vs 52%; edema 49% Who gets a MET re-biopsy after osimertinib? @LungCancerRx @OncoAlert @oncodaily
1
4
257
Aakash Desai retweeted
Adam C Palmer@ac_palmer9h
Anyone interested in cancer medicine needs to see the current front page of @NEJM nejm.org It's one historic advance after another after another on there right now
10
94
8
400
18,905
OptiTROP-Lung06 #ESMO26: 1L sac-TMT+pembro vs chemo-IO, PD-L1-neg nsq NSCLC ➡️ mPFS 15.0 vs 5.7 mo, HR 0.49 ➡️ ORR 50.2 vs 47.3%, mDOR 13.6 vs 6.8 mo ➡️ OS HR 0.58, immature ➡️ G≥3 TEAEs 47.6 vs 60.6% What must ADCs show to replace platinum? @LungCancerRx @OncoAlert @oncodaily
4
8
503
New in J Cancer Policy: lower-dose ICIs ➡️ Pembro 2, nivo 2, atezo 10 mg/kg ➡️ Est. Medicare savings 2018–2021: nearly $1.44B ➡️ Nivo $943.1M, pembro $382.2M, atezo $114.4M What moves first: FDA, CMS or vials? doi.org/10.1016/j.jcpo.2026.… @LungCancerRx @OncoAlert @oncodaily
3
8
429
#ESMO26 Phase 1 Temab-A (c-Met ADC), NSQ NSCLC @abbvie ➡️ EGFR WT (n=48): ORR 50%, mPFS 6.8, mOS 13.8 mo ➡️ EGFRm (n=41): ORR 63%, mPFS 10.9, mOS 16.2 mo ➡️ WT c-Met 3+ ≥10%: mOS 25.2 vs 9.7 mo Small changes to payload, big impact? @LungCancerRx @OncoAlert @oncodaily
1
4
12
802
👏👏 Amazing results for our #SCLC patients! Delighted that such a critical advance in a difficult to treat #cancer will forever be my first @NEJM! @SclcSMASHERS @LungCancerRx @OncoAlert @OncBrothers @sands_jacob
Aakash Desai@ADesaiMDOct 24
#ESMO26 DeLLphi-305: tarlatamab+durva vs durva, 1L maintenance ES-SCLC ➡️ OS 21.1 vs 12.7 mo, HR 0.42 ➡️ PFS 7.4 vs 1.9 mo, HR 0.34 ➡️ CRS 49.6% (G3+ 0.4%) Amazing to be part of this practice-changing study on the global steering committee!! @LungCancerRx @OncoAlert @oncodaily
3
10
36
1,891
🚨🔥@OncoAlert Hot off the press. Just published @NEJM in conjunction with presentation @myESMO #ESMO26 the long-awaited #PracticeChanging results of: ⭐️#DeLLphi305 phase 3 trial of: ❇️1st line maintenance #Tarlatamab + #Durvalumab) vs #Durvalumab alone in patients with #ExtensiveStage #SmallCell #LungCancer after initial induction Tx with #Chemo + Durvalumab. Study showed: ‼️#Impressive statistically significant & clinically meaningful ⬆️#OverallSurvival Benefit. ✅#mOS: 21.1 vs 12.7 months (HR 0.42) ✅12-month OS: 79.4% vs 53.3% ✅#mPFS: 7.4 vs 1.9 months (HR 0.34) ⚠️ Grade ≥3 #AEs: 46.8% vs 40.6% * In Tarlatamab arm: #CRS: 49.6% (Grade ≥3: 0.4%) #ICANS: 1.1% (Grade ≥3: 0%) 👇🏻 nejm.org/doi/full/10.1056/NE…
3
44
4
84
5,775
Wow incredible news for our patients with ES-SCLC! #ESMO26
Aakash Desai@ADesaiMDOct 24
#ESMO26 DeLLphi-305: tarlatamab+durva vs durva, 1L maintenance ES-SCLC ➡️ OS 21.1 vs 12.7 mo, HR 0.42 ➡️ PFS 7.4 vs 1.9 mo, HR 0.34 ➡️ CRS 49.6% (G3+ 0.4%) Amazing to be part of this practice-changing study on the global steering committee!! @LungCancerRx @OncoAlert @oncodaily
5
14
1,206
WOW! BIG news for our patients with extensive-stage small cell lung cancer! Phase 3 DeLLphi-305 trial, adding tarlatamab to durvalumab maintenance after initial chemoIO: ✅ OS: 21.1 vs 12.7 months (HR 0.42) ✅ PFS: 7.4 vs 1.9 months (HR 0.34) Practice-changed! #ESMO26
Aakash Desai@ADesaiMDOct 24
#ESMO26 DeLLphi-305: tarlatamab+durva vs durva, 1L maintenance ES-SCLC ➡️ OS 21.1 vs 12.7 mo, HR 0.42 ➡️ PFS 7.4 vs 1.9 mo, HR 0.34 ➡️ CRS 49.6% (G3+ 0.4%) Amazing to be part of this practice-changing study on the global steering committee!! @LungCancerRx @OncoAlert @oncodaily
1
19
2
66
3,492
Wonderful!! Thanks @ADesaiMD 👇👇👇
Aakash Desai@ADesaiMDOct 24
#ESMO26 DeLLphi-305: tarlatamab+durva vs durva, 1L maintenance ES-SCLC ➡️ OS 21.1 vs 12.7 mo, HR 0.42 ➡️ PFS 7.4 vs 1.9 mo, HR 0.34 ➡️ CRS 49.6% (G3+ 0.4%) Amazing to be part of this practice-changing study on the global steering committee!! @LungCancerRx @OncoAlert @oncodaily
1
2
242
DeLLphi-305 (LBA3, #ESMO26): tarlatamab + durvalumab vs durvalumab maintenance in ES-SCLC. Circulating figures: OS 21.1 vs 12.7 mo (HR 0.42); 12-mo OS 79.4% vs 53.3%. CRS frequent, G≥3 rare. Confirm at PS I. @sands_jacob @ADesaiMD #LCSM #OncoAlert
11
9
636
#ESMO26 DeLLphi-305: tarlatamab+durva vs durva, 1L maintenance ES-SCLC ➡️ OS 21.1 vs 12.7 mo, HR 0.42 ➡️ PFS 7.4 vs 1.9 mo, HR 0.34 ➡️ CRS 49.6% (G3+ 0.4%) Amazing to be part of this practice-changing study on the global steering committee!! @LungCancerRx @OncoAlert @oncodaily
3
24
4
58
8,409
Aakash Desai retweeted
Jay@buymoremakemoreOct 23
Huge win for TCEs for solid tumors in a combo therapy setting. $cntx if they get their funding figured out potentially can have their CLDN-6 and/or Nectin-4 TCE as a combo therapy. Nectin-4 especially would be very interesting as a combo therapy with Padcev + something else
Aakash Desai@ADesaiMDOct 23
Replying to @ADesaiMD @myESMO @LungCancerRx @OncoAlert @oncodaily
3/ DeLLphi-305 (LBA3), Oct 24, 17:18 CEST Tarlatamab + durvalumab as 1L maintenance in ES-SCLC. Amgen reports an OS win at interim. How large, and can clinics deliver T-cell engager monitoring in maintenance? @LungCancerRx @OncoAlert @oncodaily
1
1
4
438
🚨Great news for patients with #EGFRex20ins #lungcancer #Sunvozertinib finally available for dispensation in the US following FDA approval in July 2025. 📌 Approved for previously treated patients based on WU-KONG1B: 🔹 ORR: 46% (95% CI 35–57) 🔹 DoR: 11.1 mo (95% CI 8.2–NE) 📊 In the WU-KONG28 Phase III trial, first-line sunvozertinib vs carbo/pem (n=324) showed: 🔹 ORR: 59% vs 31% 🔹 DoR: 11.2 vs 7.1 mo 🔹 PFS: 10.3 vs 7.5 mo (HR 0.65) 🔹 12-mo PFS: 46% vs 27% 💊 200mg po daily ⚠️ Monitor for ILD/pneumonitis, GI and skin toxicity, ocular toxicity ⚠️ Diarrhea: 75% G3+: 5%) @EGFRResisters
7
1
17
2,119
1/ My top 7 thoracic picks for #ESMO26 (Madrid, Oct 23–27), ranked. @myESMO 5 of these phase 3s already announced positive toplines. ESMO is where we finally see effect sizes. The question each one answers 🧵 #LCSM @LungCancerRx @OncoAlert @oncodaily
1
8
17
1,687
more replies
7/ Early-phase ADCs: ABBV-706 (3837RO, Oct 26, 10:15 CET), SEZ6 ADC in relapsed SCLC. Where does it fit next to DLL3 and B7-H3? Temab-A (2658RO, Oct 24, 09:27 CEST), c-Met ADC, phase 1 OS in NSQ NSCLC. Does c-Met level select who benefits? @LungCancerRx @OncoAlert @oncodaily
1
1
163
8/ Full cards in the graphic. What's on your #ESMO26 lung list that I missed? #LCSM @LungCancerRx @OncoAlert @oncodaily
1
1
122
Load more